High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial
Published Online: 2024-10-?
Journal: The Lancet Respiratory Medicine•Publisher: Elsevier BV
Authors: Anhui Shi•Anhui Shi•Dan Yang•Dan Yang•Hanxiao Chen•Hanxiao Chen•Huiming Yu•Huiming Yu•Jiayi Yu•Jiayi Yu•Jinghua Luo•Jun Yang•Jun Zhao•Jun Zhao•Leilei Jiang•Leilei Jiang•Li Chu•Lina Zhao•Lina Zhao•Min Zhang•Min Zhang•Minglei Zhuo•Minglei Zhuo•Qifeng Wang•Qifeng Wang•Quanfu Li•Quanfu Li•Rong Yu•Rong Yu•Shixin Liu•Tao Gu•Wei Huang•Wei Huang•WenLi Chen•Xiaomin Wang•Xiaomin Wang•Xue Yang•Xue Yang•Yanli Qu•Yanli Qu•Yidian Zhao•Yipeng Song•Yipeng Song•Yiqun Wu•Yun Bai•Zhanshu Ma•Zhanshu Ma•Zhengfei Zhu•Zhengfei Zhu
